Digestive Diseases and Sciences

, Volume 53, Issue 2, pp 522–528 | Cite as

HLA DRB1*13 as a Risk Factor for Type 1 Autoimmune Hepatitis in North American Patients

  • Albert J. Czaja
  • Herschel A. Carpenter
  • S. Breanndan Moore
Original Paper


Our goal was to determine if HLA DRB1*13 is associated with autoimmune hepatitis in North American patients. Two hundred and ten adults with definite type 1 autoimmune hepatitis were typed by DNA-based techniques, and the frequency of HLA DRB1*13 in patients without DRB1*03 and DRB1*04 was compared to that in 396 patients with eight other chronic liver diseases and 102 normal individuals. HLA DRB1*13 occurred more commonly in the autoimmune patients who lacked DRB1*03 and DRB1*04 than normal subjects who were similarly restricted (56% vs. 27%, P = 0.007). The frequency of HLA DRB1*13 was higher in autoimmune patients without DRB1*03 and DRB1*04 than in patients with other chronic liver diseases who were similarly restricted (59% vs. 32%, P = 0.01). Only patients with primary sclerosing cholangitis had a comparable occurrence of HLA DRB1*13. In conclusion, HLA DRB1*13 may be a genetic risk factor for some white North American patients with type 1 autoimmune hepatitis.


Genetic predisposition Susceptibility factor Distinctions 


  1. 1.
    Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, Badia I, Remondino G, Ciocca M, Ramonet M, Fainboim H, Satz ML (1994) Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 41:146–150PubMedCrossRefGoogle Scholar
  2. 2.
    Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Canero-Velasco C, Fainboim L (1999) Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 30:1374–1380PubMedCrossRefGoogle Scholar
  3. 3.
    Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Carrilho FJ, Farias AQ, Palacios SA, Chiarella JM, Abrantes-Lemos CP, Baggio VL, Laudanna AA, Kalil J (1999) Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 94:1906–1913PubMedCrossRefGoogle Scholar
  4. 4.
    Goldberg AC, Bittencourt PL, Mougin B, Cancado ELR, Porta G, Carrilho F, Kalil J (2001) Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 62:165–169PubMedCrossRefGoogle Scholar
  5. 5.
    Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R (1991) Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13:701–706PubMedGoogle Scholar
  6. 6.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1993) Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502–1507PubMedGoogle Scholar
  7. 7.
    Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston ALWF, Mowat AP, Williams R (1994) Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19:609–615PubMedCrossRefGoogle Scholar
  8. 8.
    Fainboim L, Velasco VCC, Marcos CY, Ciocca M, Roy A, Theiler G, Capucchio M, Nuncifora S, Sala L, Zelazko M (2001) Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology 33:1512–1517PubMedCrossRefGoogle Scholar
  9. 9.
    Lango-Warensjo A, Cardell K, Lindblom B (1998) Haplotypes comprising subtypes of the HLA-DQB1*06 allele direct the antibody response after immunization with hepatitis B surface antigen. Tissue Antigens 52:374–380PubMedGoogle Scholar
  10. 10.
    Czaja AJ, Souto EO, Bittencourt PL, Cancado ELR, Porto G, Goldberg AC, Donaldson PT (2002) Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 37:302–308PubMedCrossRefGoogle Scholar
  11. 11.
    Czaja AJ, Carpenter HA, Moore SB (2006) Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int 26:552–558PubMedCrossRefGoogle Scholar
  12. 12.
    Czaja AJ, Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479–497PubMedCrossRefGoogle Scholar
  13. 13.
    Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WGE, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston ALWF, Fainboim L, Heathcote J, Homberg J-C, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RNM, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Nakanuma Y, Nishioka M, Penner E, Porta G, Portmann BC, Reed WD, Rodes J, Schalm SW, Scheuer PJ, Schrumpf E, Seki T, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M (1999) International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938PubMedCrossRefGoogle Scholar
  14. 14.
    Czaja AJ (2005) Autoantibodies in autoimmune liver disease. Adv Clin Chem 40:127–164PubMedCrossRefGoogle Scholar
  15. 15.
    Czaja AJ (2005) Current concepts in autoimmune hepatitis. Ann Hepatol 4:6–24PubMedGoogle Scholar
  16. 16.
    Czaja AJ, Carpenter HA (1993) Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832PubMedGoogle Scholar
  17. 17.
    Czaja AJ, Santrach PJ, Moore SB (2001) Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 46:140–147PubMedCrossRefGoogle Scholar
  18. 18.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1996) Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 24:52–59PubMedCrossRefGoogle Scholar
  19. 19.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA (1993) The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104:1755–1761PubMedGoogle Scholar
  20. 20.
    Czaja AJ, Donaldson PT (2000) Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 174:250–259PubMedCrossRefGoogle Scholar
  21. 21.
    Czaja AJ, Doherty DG, Donaldson PT (2002) Genetic bases of autoimmune hepatitis. Dig Dis Sci 47:2139–2150PubMedCrossRefGoogle Scholar
  22. 22.
    Donaldson PT, Czaja AJ (2002) Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 6:707–725PubMedCrossRefGoogle Scholar
  23. 23.
    Donaldson PT (2002) Genetics in autoimmune hepatitis. Semin Liver Dis 22:353–364PubMedCrossRefGoogle Scholar
  24. 24.
    Doherty DG, Penzotti JE, Koelle DM, Kwok WW, Lybrand TP, Masewicz S, Nepom GT (1998) Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 161:3527–3535PubMedGoogle Scholar
  25. 25.
    Singal DP, Li J, Zhu Y (1999) Genetic basis for rheumatoid arthritis. Arch Immunol Ther Exp 47:307–311Google Scholar
  26. 26.
    Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka-Kido J (1999) Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 61:825–829PubMedGoogle Scholar
  27. 27.
    Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D (1991) Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 337:1183–1187PubMedCrossRefGoogle Scholar
  28. 28.
    Huppertz H-K, Treichel U, Gassel AM, Jeschke R, Meyer zum Buschenfelde K-H (1995) Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 23:204–208PubMedCrossRefGoogle Scholar
  29. 29.
    Tanaka H, Tujioka H, Ueda H, Hamagami H, Kida Y, Ichinose M (2005) Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol 11:6069–6071PubMedGoogle Scholar
  30. 30.
    Schreuder GM, Hurley CK, Marsh SG, Lau M, Maiers M, Kollman C, Noreen HJ (2001) The HLA dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and –DQ antigens. Hum Immunol 62:826–849PubMedCrossRefGoogle Scholar
  31. 31.
    Hill A, Allsopp C, Kwiatkowski D, Anstey N, Twumasi P, Rowe P, Bennet S, Brewster D, McMichael AJ, Greenwood BM (1991) Common West African HLA antigens are associated with protection from severe malaria. Nature 352:595–600PubMedCrossRefGoogle Scholar
  32. 32.
    Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, Eddleston ALWF, Williams R (1992) Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 16:390–395PubMedCrossRefGoogle Scholar
  33. 33.
    Boberg KM, Spurkland A, Rocca G, Egeland T, Saarinen S, Mitchell S, Broome U, Chapman R, Olerup O, Pares A, Rosina F, Schrumpf E (2001) The HLA-DR3, Dq2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 36:886–890PubMedCrossRefGoogle Scholar
  34. 34.
    Donaldson PT, Norris S (2001) Immunogenetics in PSC. Best Practice Res Clin Gastroenterol 15:611–627CrossRefGoogle Scholar
  35. 35.
    Donaldson PT, Norris S (2002) Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 35:555–564PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Albert J. Czaja
    • 1
  • Herschel A. Carpenter
    • 2
  • S. Breanndan Moore
    • 2
  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA
  2. 2.Department of Laboratory Medicine and PathologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations